Addex stock tanks after lead drug flops in Phase II epilepsy trial
Addex and J&J co-developed the allosteric modulator therapy, which failed to meet the primary endpoint in a Phase II epilepsy trial.
Addex and J&J co-developed the allosteric modulator therapy, which failed to meet the primary endpoint in a Phase II epilepsy trial.
Klineo plans to expand its AI platform to include all cancers in France by the end of 2024, and eventually other countries and diseases.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Hyperfine starts enrolment in portable imaging workflow study
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
Cleerly touts new data for AI cardiovascular software
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints